Pharmacotherapy of atrial fibrillation

A pathophysiological perspective and review

Sony Jacob, Omaima Ali, Victoria Pidlaoan, Apurva O. Badheka, Nicholas Z. Kerin

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

Atrial fibrillation (AF) is one of the most common arrhythmia encountered in clinical practice. Although AF is due to the structural and electrophysiological alterations in the atria, its sustainability is multifactorial, and the actual mechanisms are still not clear. Despite the recent advances in catheter ablation technology and techniques, pharmacotherapy still remains the first-line therapy for the management of AF. Current pharmacotherapy targets ion channel alterations that in fact represent only one aspect of the management of this complex arrhythmia. Successful pharmacological treatment of AF and restoration of sinus rhythm is limited and is in part due to its potential deleterious side effects. Newer agents having diverse mechanisms acting on the recently uncovered pathophysiological processes are on the horizon. These include atrial repolarization delaying agents, newer class III agents, Na +-Ca 2+ channel blockers, stretch receptor blockers, I KACH blockers, gap junction modifiers, upstream therapies, and agents targeting ischemia-induced AF. Gene- and cell-specific therapies including 'tailored nanopharmacy,' newer rate control medications with minimal side effects and the emergence of novel drugs targeting multiple areas of AF arrhythmogenesis in tandem with electrical therapy may be the future direction in the management of AF.

Original languageEnglish (US)
Pages (from-to)241-260
Number of pages20
JournalAmerican Journal of Therapeutics
Volume18
Issue number3
DOIs
StatePublished - May 1 2011

Fingerprint

Atrial Fibrillation
Drug Therapy
Cardiac Arrhythmias
Ablation Techniques
Mechanoreceptors
Catheter Ablation
Gap Junctions
Therapeutics
Drug Delivery Systems
Cell- and Tissue-Based Therapy
Ion Channels
Ischemia
Pharmacology
Technology
Genes

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Cite this

Jacob, Sony ; Ali, Omaima ; Pidlaoan, Victoria ; Badheka, Apurva O. ; Kerin, Nicholas Z. / Pharmacotherapy of atrial fibrillation : A pathophysiological perspective and review. In: American Journal of Therapeutics. 2011 ; Vol. 18, No. 3. pp. 241-260.
@article{732f1b70ce0e4362866d2e5eaf81f85c,
title = "Pharmacotherapy of atrial fibrillation: A pathophysiological perspective and review",
abstract = "Atrial fibrillation (AF) is one of the most common arrhythmia encountered in clinical practice. Although AF is due to the structural and electrophysiological alterations in the atria, its sustainability is multifactorial, and the actual mechanisms are still not clear. Despite the recent advances in catheter ablation technology and techniques, pharmacotherapy still remains the first-line therapy for the management of AF. Current pharmacotherapy targets ion channel alterations that in fact represent only one aspect of the management of this complex arrhythmia. Successful pharmacological treatment of AF and restoration of sinus rhythm is limited and is in part due to its potential deleterious side effects. Newer agents having diverse mechanisms acting on the recently uncovered pathophysiological processes are on the horizon. These include atrial repolarization delaying agents, newer class III agents, Na +-Ca 2+ channel blockers, stretch receptor blockers, I KACH blockers, gap junction modifiers, upstream therapies, and agents targeting ischemia-induced AF. Gene- and cell-specific therapies including 'tailored nanopharmacy,' newer rate control medications with minimal side effects and the emergence of novel drugs targeting multiple areas of AF arrhythmogenesis in tandem with electrical therapy may be the future direction in the management of AF.",
author = "Sony Jacob and Omaima Ali and Victoria Pidlaoan and Badheka, {Apurva O.} and Kerin, {Nicholas Z.}",
year = "2011",
month = "5",
day = "1",
doi = "10.1097/MJT.0b013e3181eea7c5",
language = "English (US)",
volume = "18",
pages = "241--260",
journal = "American Journal of Therapeutics",
issn = "1075-2765",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

Pharmacotherapy of atrial fibrillation : A pathophysiological perspective and review. / Jacob, Sony; Ali, Omaima; Pidlaoan, Victoria; Badheka, Apurva O.; Kerin, Nicholas Z.

In: American Journal of Therapeutics, Vol. 18, No. 3, 01.05.2011, p. 241-260.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Pharmacotherapy of atrial fibrillation

T2 - A pathophysiological perspective and review

AU - Jacob, Sony

AU - Ali, Omaima

AU - Pidlaoan, Victoria

AU - Badheka, Apurva O.

AU - Kerin, Nicholas Z.

PY - 2011/5/1

Y1 - 2011/5/1

N2 - Atrial fibrillation (AF) is one of the most common arrhythmia encountered in clinical practice. Although AF is due to the structural and electrophysiological alterations in the atria, its sustainability is multifactorial, and the actual mechanisms are still not clear. Despite the recent advances in catheter ablation technology and techniques, pharmacotherapy still remains the first-line therapy for the management of AF. Current pharmacotherapy targets ion channel alterations that in fact represent only one aspect of the management of this complex arrhythmia. Successful pharmacological treatment of AF and restoration of sinus rhythm is limited and is in part due to its potential deleterious side effects. Newer agents having diverse mechanisms acting on the recently uncovered pathophysiological processes are on the horizon. These include atrial repolarization delaying agents, newer class III agents, Na +-Ca 2+ channel blockers, stretch receptor blockers, I KACH blockers, gap junction modifiers, upstream therapies, and agents targeting ischemia-induced AF. Gene- and cell-specific therapies including 'tailored nanopharmacy,' newer rate control medications with minimal side effects and the emergence of novel drugs targeting multiple areas of AF arrhythmogenesis in tandem with electrical therapy may be the future direction in the management of AF.

AB - Atrial fibrillation (AF) is one of the most common arrhythmia encountered in clinical practice. Although AF is due to the structural and electrophysiological alterations in the atria, its sustainability is multifactorial, and the actual mechanisms are still not clear. Despite the recent advances in catheter ablation technology and techniques, pharmacotherapy still remains the first-line therapy for the management of AF. Current pharmacotherapy targets ion channel alterations that in fact represent only one aspect of the management of this complex arrhythmia. Successful pharmacological treatment of AF and restoration of sinus rhythm is limited and is in part due to its potential deleterious side effects. Newer agents having diverse mechanisms acting on the recently uncovered pathophysiological processes are on the horizon. These include atrial repolarization delaying agents, newer class III agents, Na +-Ca 2+ channel blockers, stretch receptor blockers, I KACH blockers, gap junction modifiers, upstream therapies, and agents targeting ischemia-induced AF. Gene- and cell-specific therapies including 'tailored nanopharmacy,' newer rate control medications with minimal side effects and the emergence of novel drugs targeting multiple areas of AF arrhythmogenesis in tandem with electrical therapy may be the future direction in the management of AF.

UR - http://www.scopus.com/inward/record.url?scp=79958036974&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79958036974&partnerID=8YFLogxK

U2 - 10.1097/MJT.0b013e3181eea7c5

DO - 10.1097/MJT.0b013e3181eea7c5

M3 - Review article

VL - 18

SP - 241

EP - 260

JO - American Journal of Therapeutics

JF - American Journal of Therapeutics

SN - 1075-2765

IS - 3

ER -